SynthesisFrontiers in pharmacology2024

The adverse events of CDK4/6 inhibitors for HR+/ HER2- breast cancer: an umbrella review of meta-analyses of randomized controlled trials.

Dongqing Pu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.